Why the study?
AF increases mortality and morbidity, and NOACs reduce ischemic events, but comparing biochemical and clinical parameters and risk factors for thrombotic complications between agents was needed.
Does dabigatran compared to rivaroxaban affect biochemical parameters and thrombotic complications in patients with atrial fibrillation?
Does dabigatran compared to rivaroxaban affect biochemical parameters and thrombotic complications in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Dabigatran-rivaroxaban differences in AF should not yet change practice; leaves open need for randomized confirmation on biochemical and thrombotic outcomes.
Introduction: Atrial fibrillation (AF) is a common disease that increases mortality and morbidity. New generation oral anticoagulants (NOACs) are agents that reduce ischemic events in patients with AF. In this study, we aim to compare biochemical and clinical parameters and examine the risk factors for thrombotic complications (such as stroke, myocardial infarction, systemic embolization) in patients using NOACs (dabigatran and rivaroxaban).
No takes yet. Share an insight, caveat, or question.
Aydın et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: